INSM · INSMED Inc

Track INSM — free

$114.14 -1.49 (-1.29%) At close · Sep 30

Russell 1000 member Rebalance outlook locked

Market Cap

$25.73B

218.38M

Volume · Sep 30 2.87M Avg daily vol (3M) 2.45M

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$1.14B

Trailing 12 months

Net income (TTM)

−$875.31M

Trailing 12 months

Revenue growth YoY

+296.1%

Year over year

Operating margin

-73.9%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-3.1%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+14.8%

Year over year · more shares

Price change (1Y)

-18.4%

Trailing year

Short interest

4.9%

Latest settlement · 5.3 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −15%

below

Price vs 50-day avg −5%

below

RSI (14) 39

neutral

MACD trend Negative

52-week position 19%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −6%

trailing

6-month return −28%

trailing

YTD return −34%

this year

Relative strength −41%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $120 › 200d $134 — 200d above 50d

Institutional flow Distributing

-2% holders QoQ · +114 funds added

Insider flow Distributing

Net -$35.7M over 90 days · 100% sells

Short interest Falling

4.95% of float · ▼ -5.6% MoM · 5.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

670 holders — near 3-yr high, broad support

Squeeze score 62

elevated · 0–100

Fundamentals

Poor

EPS growth −15%

Y/Y

Free cash flow $-967.6M

Balance sheet $36.3M

net debt

Quant / Vol

risk profile

Very High

Volatility 62%

annualized · 1-yr

Max drawdown −57%

past year

ATR 4.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 6, 2026

full-year 2026

BRINSUPRI revenues Initiated $1.25B – $1.4B

ARIKAYCE revenues Initiated $450M – $470M

peak

BRINSUPRI peak revenue estimate at least $7B

TPIP peak revenue estimate at least $6B

ARIKAYCE peak revenue estimate at least $1B

Full-Year 2026

BRINSUPRI Revenue Initiated $1.25B – $1.4B

ARIKAYCE Revenue Initiated $450M – $470M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

2 · 5 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−15% Bearish

Price vs 50-day avg

−5% Neutral

RSI (14)

39 Neutral

MACD trend

Negative Bearish

52-week position

19% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $120 › 200d $134 — 200d above 50d

Institutional flow Distributing

-2% holders QoQ · +114 funds added

Insider flow Distributing

Net -$35.7M over 90 days · 100% sells

Short interest Falling

4.95% of float · ▼ -5.6% MoM · 5.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

670 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $92 Now $114 · 19% Range high $211

vs 200-day avg -15% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INSM INSMED Inc this stock	$25.73B	-34.4%	+66.7%	—	4.9%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

670

% held: 106.3%
Net QoQ: +9.7M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

667

View

Short & Settlement

Short Interest Falling

Shares short

10.8M

Days to cover: 5.3d
Change: -638.1K sh

View

Short Volume

Short vol %

45%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

152

Value: $19.2K
As of: Sep 3, 2026

View

Off-Exchange

Off-exchange %

51.7%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$35.7M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Congressional Trades Sell

Member

Josh Gottheimer

Amount: $1.0K–$15.0K
Traded: Jun 10, 2026

View

Financials

Revenue (FY)

$606.4M

Net income (FY): $-1.3B
EPS diluted: $-6.42

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 14, 2026
This year: 14

View

Proposed Sales

Value

$3.1M

Shares: 25.0K
Filed: Sep 10, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 14, 2026

View

Performance

	5D	20D	120D	MTD	YTD
INSM	-3.6%	-6.1%	-28.5%	-6.3%	-34.4%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-2.9%	-6.2%	-40.7%	-5.7%	-46.3%

Key facts CIK 1104506 CUSIP 457669307 13F (30d) 16 filings 13 filers Visit website Investor relations

INSM · INSMED Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance